https://www.escardio.org/communities/working-groups/thrombosis/scientific-documents-and-publications/commented-articles/asundexian-versus-apixaban-in-patients-with-atrial-fibrillation/
Asundexian versus Apixaban in Patients with Atrial Fibrillation
in patientsasundexianversusapixabanatrial
https://www.straitstimes.com/world/europe/bayer-cancels-asundexian-phase-iii-study-program
Bayer cancels asundexian phase III study programme | The Straits Times
Nov 12, 2024 - Germany's Bayer AG said on Sunday it is cancelling a phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa)...
phase iii studythe straitsbayercancelsasundexian